Risedronate Sodium

CAS No. 115436-72-1

Risedronate Sodium( —— )

Catalog No. M10542 CAS No. 115436-72-1

Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 28 In Stock
100MG 37 In Stock
200MG Get Quote In Stock
500MG 68 In Stock
1G 91 In Stock

Biological Information

  • Product Name
    Risedronate Sodium
  • Note
    Research use only, not for human use.
  • Brief Description
    Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
  • Description
    Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HAP| FPS
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    115436-72-1
  • Formula Weight
    305.09
  • Molecular Formula
    C7H10NNaO7P2
  • Purity
    >98% (HPLC)
  • Solubility
    Water: 2 mg/mL (6.55 mM)
  • SMILES
    O.O.O.O.O.[Na+].OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O.OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bergstrom JD, et al. Arch Biochem Biophys. 2000 Jan 1;373(1):231-4
molnova catalog
related products
  • Pamidronate disodium...

    Pamidronate disodium, a bisphosphonate drug,  can help to strengthen bones.

  • HEC72702

    HEC72702 is a novel potent, orally active inhibitor of HBV capsid assembly, inhibits HBV-DNA levels in HepG.2.2.15 cells with IC50 of 39 nM.

  • Metacavir

    Metacavir (PNA) is a novel nucleoside reverse transcriptase inhibitor, a deoxyguanosine analog, with anti-hepatitis B virus (HBV) activity and mitochondrial toxicity, which can be used to study HBV infection.